{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:51:05Z","timestamp":1781877065032,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000056","name":"National Institute of Nursing Research","doi-asserted-by":"publisher","award":["82090054"],"award-info":[{"award-number":["82090054"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04244-5","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:51:55Z","timestamp":1770126715000},"page":"2803-2814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT\/mTOR signaling pathway"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9439-938X","authenticated-orcid":false,"given":"Hanchuan","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"8","key":"4244_CR1","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1007\/s10620-022-07433-8","volume":"67","author":"A Ramani","year":"2022","unstructured":"Ramani A, Tapper EB, Griffin C, Shankar N, Parikh ND, Asrani SK. Hepatocellular carcinoma-related mortality in the USA, 1999\u20132018. Dig Dis Sci. 2022;67(8):4100\u201311.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"4244_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/15569543.2018.1446027","volume":"38","author":"N Habibi","year":"2019","unstructured":"Habibi N, Nassiri-Toosi M, Sharafi H, Alavian SM, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Aflatoxin B1 exposure and the risk of hepatocellular carcinoma in Iranian carriers of viral hepatitis B and C. Toxin Rev. 2019;38(3):234\u20139.","journal-title":"Toxin Rev"},{"key":"4244_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El\u2010Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4\u201313.","journal-title":"Hepatology"},{"key":"4244_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.683719","volume":"9","author":"R Melaram","year":"2021","unstructured":"Melaram R. Environmental risk factors implicated in liver disease: a mini-review. Front Public Health. 2021;9:683719.","journal-title":"Front Public Health"},{"issue":"3","key":"4244_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.21037\/jgo-22-404","volume":"13","author":"J Zhai","year":"2022","unstructured":"Zhai J, Liu J, Fu Z, Bai S, Li X, Qu Z, et al. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study. J Gastrointest Oncol. 2022;13(3):1278.","journal-title":"J Gastrointest Oncol"},{"key":"4244_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s10637-019-00801-8","volume":"38","author":"S Ogasawara","year":"2020","unstructured":"Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs. 2020;38:172\u201380.","journal-title":"Invest New Drugs"},{"key":"4244_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920927602","volume":"12","author":"G Fan","year":"2020","unstructured":"Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol. 2020;12:1758835920927602.","journal-title":"Ther Adv Med Oncol"},{"key":"4244_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111194","author":"Y Sun","year":"2022","unstructured":"Sun Y, Zhang H, Meng J, Guo F, Ren D, Wu H, et al. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K\/AKT pathway. Cell Rep. 2022. https:\/\/doi.org\/10.1016\/j.celrep.2022.111194.","journal-title":"Cell Rep"},{"issue":"12","key":"4244_CR9","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019103181","volume":"39","author":"Z Lin","year":"2020","unstructured":"Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, et al. RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO 3-mediated autophagy. EMBO J. 2020;39(12):e103181.","journal-title":"EMBO J"},{"issue":"1","key":"4244_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-023-04008-6","volume":"23","author":"F-F Tang","year":"2023","unstructured":"Tang F-F, Liu L, Tian X-T, Li N, Peng Y-X, Qian C-M, et al. Network pharmacological analysis of corosolic acid reveals P4HA2 inhibits hepatocellular carcinoma progression. BMC Complement Med Ther. 2023;23(1):171.","journal-title":"BMC Complement Med Ther"},{"key":"4244_CR11","doi-asserted-by":"publisher","unstructured":"Ho M-Y, Hong Q-T, Bao T-Y, Shen H-R, Chen J-C, Guo XG. Comprehensive analysis of immune implication and prognostic value of CCDC137 in hepatocellular carcinoma. 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-2903053\/v1.","DOI":"10.21203\/rs.3.rs-2903053\/v1"},{"issue":"2","key":"4244_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2023.13911","volume":"26","author":"J Wu","year":"2023","unstructured":"Wu J, Yue C, Xu W, Li H, Zhu J, Li L. MNX1 facilitates the malignant progress of lung adenocarcinoma through transcriptionally upregulating CCDC34. Oncol Lett. 2023;26(2):1\u201312.","journal-title":"Oncol Lett"},{"issue":"10","key":"4244_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1087","volume":"12","author":"W Dai","year":"2022","unstructured":"Dai W, Wu J, Peng X, Hou W, Huang H, Cheng Q, et al. CDK12 orchestrates super\u2010enhancer\u2010associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer. Clin Transl Med. 2022;12(10):e1087.","journal-title":"Clin Transl Med"},{"issue":"4","key":"4244_CR14","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/tox.24105","volume":"39","author":"X Xudong","year":"2024","unstructured":"Xudong X, Heng L, Benchao C, Wenjie C, Bao L, Gaofeng L. Integrated RNA expression and alternative polyadenylation analysis identified CPSF1-CCDC137 oncogenic axis in lung adenocarcinoma. Environ Toxicol. 2024;39(4):2405\u201316.","journal-title":"Environ Toxicol"},{"key":"4244_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4234116","volume":"2022","author":"J Mo","year":"2022","unstructured":"Mo J, Da X, Li Q, Huang J, Lu L, Lu H. The study of exosomes-encapsulated mPEG-PLGA polymer drug-loaded particles for targeted therapy of liver cancer. J Oncol. 2022;2022:4234116.","journal-title":"J Oncol"},{"issue":"18","key":"4244_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184353","volume":"20","author":"S Donati","year":"2019","unstructured":"Donati S, Ciuffi S, Brandi ML. Human circulating miRNAs real-time qRT-PCR-based analysis: an overview of endogenous reference genes used for data normalization. Int J Mol Sci. 2019;20(18):4353.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4244_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrd.2018.146","volume":"18","author":"J Dawkins","year":"2019","unstructured":"Dawkins J, Webster RM. The hepatocellular carcinoma market. Nat Rev Drug Discov. 2019;18(1):13\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4244_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3350\/cmh.2019.0031","volume":"26","author":"A Makol","year":"2020","unstructured":"Makol A, Kaur H, Sharma S, Kanthaje S, Kaur R, Chakraborti A. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line. Clin Mol Hepatol. 2020;26(1):45.","journal-title":"Clin Mol Hepatol"},{"key":"4244_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-016-0430-z","volume":"35","author":"Z Qu","year":"2016","unstructured":"Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. J Exp Clin Cancer Res. 2016;35:1\u201312.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"4244_CR20","doi-asserted-by":"publisher","first-page":"e78675","DOI":"10.1371\/journal.pone.0078675","volume":"8","author":"AK-M Chow","year":"2013","unstructured":"Chow AK-M, Ng L, Lam CS-C, Wong SK-M, Wan TM-H, Cheng NS-M, et al. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PloS one. 2013;8(11):e78675.","journal-title":"PloS one"},{"key":"4244_CR21","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55806","volume":"9","author":"F Zhang","year":"2020","unstructured":"Zhang F, Bieniasz PD. HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. Elife. 2020;9:e55806.","journal-title":"Elife"},{"key":"4244_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.674863","volume":"8","author":"L Guo","year":"2021","unstructured":"Guo L, Li B, Lu Z, Liang H, Yang H, Chen Y, et al. CCDC137 is a prognostic biomarker and correlates with immunosuppressive tumor microenvironment based on pan-cancer analysis. Front Mol Biosci. 2021;8:674863.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"4244_CR23","volume":"2022","author":"L Bai","year":"2022","unstructured":"Bai L, Yang Z-X, Liu J-S, Wang D-S, Yu H-C. Prognostic significance of CCDC137 expression and its association with immune infiltration in hepatocellular carcinoma. Dis Markers. 2022;2022(1):5638675.","journal-title":"Dis Markers"},{"key":"4244_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01328-z","author":"L Xu","year":"2024","unstructured":"Xu L, Liu Q, Liu H, Fan F, Li P, Yue S, et al. Disrupting CCDC137-mediated LZTS2 and \u03b2-TrCP interaction in the nucleus inhibits hepatocellular carcinoma development via \u03b2-catenin and AKT. Cell Death Differ. 2024. https:\/\/doi.org\/10.1038\/s41418-024-01328-z.","journal-title":"Cell Death Differ"},{"issue":"5","key":"4244_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/10409238.2021.1934811","volume":"56","author":"M Cirone","year":"2021","unstructured":"Cirone M. Cancer cells dysregulate PI3K\/AKT\/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses. Crit Rev Biochem Mol Biol. 2021;56(5):500\u20139.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"1","key":"4244_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00416-0","volume":"10","author":"F Xu","year":"2020","unstructured":"Xu F, Na L, Li Y, Chen L. RETRACTED article: roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2020;10(1):54.","journal-title":"Cell Biosci"},{"issue":"19","key":"4244_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910260","volume":"22","author":"C Stefani","year":"2021","unstructured":"Stefani C, Miricescu D, Stanescu-Spinu I-I, Nica RI, Greabu M, Totan AR, et al. Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? Int J Mol Sci. 2021;22(19):10260.","journal-title":"Int J Mol Sci"},{"key":"4244_CR28","doi-asserted-by":"crossref","unstructured":"Revathidevi S, Munirajan AK, editors. Akt in cancer: Mediator and more. Seminars in cancer biology; 2019: Elsevier.","DOI":"10.1016\/j.semcancer.2019.06.002"},{"issue":"9","key":"4244_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797.","journal-title":"Cell Death Dis"},{"key":"4244_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.655731","volume":"9","author":"N Deleyto-Seldas","year":"2021","unstructured":"Deleyto-Seldas N, Efeyan A. The mTOR\u2013autophagy axis and the control of metabolism. Front Cell Dev Biol. 2021;9:655731.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"4244_CR31","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","volume":"478","author":"K Ramasubbu","year":"2023","unstructured":"Ramasubbu K, Devi Rajeswari V. Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem. 2023;478(6):1307\u201324.","journal-title":"Mol Cell Biochem"},{"key":"4244_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2018.04.072","volume":"103","author":"J Yang","year":"2018","unstructured":"Yang J, Pi C, Wang G. Inhibition of PI3K\/Akt\/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother. 2018;103:699\u2013707.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4244_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03416-5","volume":"20","author":"Z Pu","year":"2022","unstructured":"Pu Z, Duda DG, Zhu Y, Pei S, Wang X, Huang Y, et al. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K\/AKT\/mTOR pathway. J Transl Med. 2022;20(1):212.","journal-title":"J Transl Med"},{"key":"4244_CR34","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.1007\/s13277-015-4707-1","volume":"37","author":"B Zhai","year":"2016","unstructured":"Zhai B, Zhang X, Sun B, Cao L, Zhao L, Li J, et al. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. Tumor Biology. 2016;37:8047\u201355.","journal-title":"Tumor Biology"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04244-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04244-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04244-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:57:51Z","timestamp":1781873871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04244-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4244"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04244-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}